PreciseDx – Weekly Recap

PreciseDx, an artificial intelligence-driven digital pathology company focused on oncology diagnostics, featured prominently across several industry and advocacy events this week, underscoring its efforts to advance and commercialize its breast cancer decision-support platform. This weekly summary highlights the company’s recent presentations, scientific validation activities, and ecosystem engagement around its OncoIntelligence platform and flagship PreciseBreast test.

A central theme across the updates is the positioning of PreciseBreast as an AI-powered digital pathology tool designed to predict breast cancer recurrence risk within hours by analyzing tumor phenotype and grade. At the TME Fall Summit in New Orleans, the company showcased PreciseBreast during a Tech Crunch-style forum, with Vice President of Commercial Ted Diehl presenting data on recurrence-risk prediction and engaging with clinicians and industry stakeholders at the company’s booth. This presence reinforces PreciseDx’s push to demonstrate real-world clinical utility and build commercial visibility for its technology.

Scientific validation remains a key pillar of the company’s strategy. PreciseDx announced that three scientific presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS25) will feature new data on PreciseBreast. The abstracts cover use of the test on biopsy specimens to predict recurrence, an AI-enabled phenotyping approach for triple-negative breast cancer, and a real-world evaluation of the test for risk stratification in early-stage invasive breast cancer in collaboration with Lankenau Medical Center/Main Line Health. These efforts indicate ongoing work to strengthen the clinical evidence base, which is important for clinician adoption, reimbursement decision-making, and potential partnerships with health systems and pathology labs.

The company also emphasized thought leadership and collaboration in AI-enabled oncology. At the Healthcare, AI and Cancer: India–US Partnership Summit 2025, held in collaboration with Mount Sinai, Chief Scientific Officer and Co-Founder Gerardo Fernandez and VP of AI & Technology Vijay Yadav highlighted the OncoIntelligence platform’s role in digital pathology and expanding access to advanced breast cancer care technologies globally. Separately, CEO Eric Converse’s participation in an HLTH USA 2025 panel alongside Merck Oncology and the Patient Empowerment Network, and Yadav’s role moderating a NYC Leadership Summit panel with Kyowa Kirin, Memorial Sloan Kettering, and AstraZeneca, signal deepening engagement with biopharmaceutical, clinical, and patient advocacy stakeholders.

Finally, PreciseDx continued to reinforce its breast cancer focus and brand presence through sponsorship and participation in the American Cancer Society’s Making Strides Against Breast Cancer event in New York City. By aligning with a major patient advocacy initiative, the company is seeking to raise awareness of its decision-support tools among clinicians, patients, and advocacy groups.

Taken together, this week’s developments depict PreciseDx as intensifying its dual focus on clinical validation and ecosystem visibility for its AI-based breast cancer diagnostics, activities that, if effectively executed and supported by positive data, could enhance its long-term adoption and partnership prospects in the oncology diagnostics market.